Valproic acid exerts anti-tumor as well as anti-angiogenic effects on myeloma

International Journal of Hematology

Volumn 89, Issue 1, 2009, Pages 45-57

  Kitazoe, Ken Ichi ^a   Abe, Masahiro ^a   Hiasa, Masahiro ^b   Oda, Asuka ^a   Amou, Hiroe ^a   Harada, Takeshi ^a   Nakano, Ayako ^a   Takeuchi, Kyoko ^a   Hashimoto, Toshihiro ^a   Ozaki, Shuji ^c   Matsumoto, Toshio ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

^b UNIVERSITY OF TOKUSHIMA   (Japan)

^c TOKUSHIMA UNIVERSITY HOSPITAL   (Japan)

Author keywords

Angiogenesis; Apoptosis; Myeloma; Osteoclast; Valproic acid

Indexed keywords

CASPASE; DEXAMETHASONE; MELPHALAN; SYNDECAN 1; THALIDOMIDE; VALPROIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BONE MARROW CELL; CANCER GROWTH; CANCER SURVIVAL; CELL CULTURE; CELL DEATH; CELL SURVIVAL; COCULTURE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG MECHANISM; FEMALE; HUMAN; HUMAN CELL; IN VIVO STUDY; MICROENVIRONMENT; MOUSE; MYELOMA; MYELOMA CELL; NONHUMAN; OSTEOCLAST;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW; CELL PROLIFERATION; CELL SURVIVAL; COCULTURE TECHNIQUES; DRUG SYNERGISM; HISTONE DEACETYLASES; HUMANS; MULTIPLE MYELOMA; OSTEOCLASTS; THALIDOMIDE; TUMOR CELLS, CULTURED; VALPROIC ACID;

EID: 67349232016     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12185-008-0226-9     Document Type: Article

References (53)

1. JA Child GJ Morgan FE Davies 2003 High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma N Engl J Med 348 1875 83 10.1056/NEJMoa022340
2. A Palumbo S Bringhen MT Petrucci 2004 Intermediate-dose melphalan improves survival of myeloma patients aged 50 to 70: results of a randomized controlled trial Blood 104 3052 7 10.1182/blood-2004-02-0408
3. MA Rogawski W Loscher 2004 The neurobiology of antiepileptic drugs Nat Rev Neurosci 5 553 64 10.1038/nrn1430
4. M Gottlicher S Minucci P Zhu 2001 Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells EMBO J 20 6969 78 10.1093/emboj/20.24.6969
5. N Gurvich OM Tsygankova JL Meinkoth PS Klein 2004 Histone deacetylase is a target of valproic acid-mediated cellular differentiation Cancer Res 64 1079 86 10.1158/0008-5472.CAN-03-0799
6. JE Bolden MJ Peart RW Johnstone 2006 Anticancer activities of histone deacetylase inhibitors Nat Rev Drug Discov 5 769 84 10.1038/nrd2133
7. MM Knupfer P Hernaiz-Driever H Poppenborg JE Wolff J Cinatl J Cinatl 1998 Valproic acid inhibits proliferation and changes expression of CD44 and CD56 of malignant glioma cells in vitro Anticancer Res 18 3585 9
8. M Abdul N Hoosein 2001 Inhibition by anticonvulsants of prostate-specific antigen and interleukin-6 secretion by human prostate cancer cells Anticancer Res 21 2045 8
9. CM Olsen ET Meussen-Elholm LS Roste E Tauboll 2004 Antiepileptic drugs inhibit cell growth in the human breast cancer cell line MCF7 Mol Cell Endocrinol 213 173 9 10.1016/j.mce.2003.10.032
10. R Kawagoe H Kawagoe K Sano 2002 Valproic acid induces apoptosis in human leukemia cells by stimulating both caspase-dependent and -independent apoptotic signaling pathways Leuk Res 26 495 502 10.1016/S0145-2126(01)00151-5
11. TV Tittle BA Schaumann 1992 Effect of antiepileptic drugs on growth of murine lymphoid tumor cells in single-cell culture Epilepsia 33 729 35 10.1111/j.1528-1157.1992.tb02354.x
12. M Kaiser I Zavrski J Sterz 2006 The effects of the histone deacetylase inhibitor valproic acid on cell cycle, growth suppression and apoptosis in multiple myeloma Haematologica 91 248 51
13. M Abe K Hiura J Wilde 2002 Role for macrophage inflammatory protein (MIP)-1alpha and MIP-1beta in the development of osteolytic lesions in multiple myeloma Blood 100 2195 202
14. M Abe K Hiura J Wilde 2004 Osteoclasts enhance myeloma cell growth and survival via cell-cell contact: a vicious cycle between bone destruction and myeloma expansion Blood 104 2484 91 10.1182/blood-2003-11-3839
15. T Oshima M Abe J Asano 2005 Myeloma cells suppress bone formation by secreting a soluble Wnt inhibitor, sFRP-2 Blood 106 3160 5 10.1182/blood-2004- 12-4940
16. Y Tanaka M Abe M Hiasa 2007 Myeloma cell-osteoclast interaction enhances angiogenesis together with bone resorption: a role for vascular endothelial cell growth factor and osteopontin Clin Cancer Res 13 816 23 10.1158/1078-0432.CCR- 06-2258
17. T Matsumoto M Abe 2006 Bone destruction in multiple myeloma Ann NY Acad Sci 1068 319 26 10.1196/annals.1346.035
18. JM Quinn J Elliott MT Gillespie TJ Martin 1998 A combination of osteoclast differentiation factor and macrophage-colony stimulating factor is sufficient for both human and mouse osteoclast formation in vitro Endocrinology 139 4424 7 10.1210/en.139.10.4424
19. A Sabokbar NS Athanasou 2003 Generating human osteoclasts from peripheral blood Methods Mol Med 80 101 11
20. TC Chou P Talalay 1984 Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors Adv Enzyme Regul 22 27 55 10.1016/0065-2571(84)90007-4
21. K Tezuka T Sato H Kamioka 1992 Identification of osteopontin in isolated rabbit osteoclasts Biochem Biophys Res Commun 186 911 7 10.1016/0006-291X(92) 90832-6
22. Y Mori N Shimizu M Dallas 2004 Anti-α4 integrin antibody suppresses the development of multiple myeloma and associated osteoclastic osteolysis Blood 104 2149 54 10.1182/blood-2004-01-0236
23. IR Garrett T Dallas J Rada GRH Nundy 1997 A murine model of human myeloma bone disease Bone 20 515 20 10.1016/S8756-3282(97)00056-2
24. SL Dallas IR Garrett BO Oyajobi 1999 Ibandronate reduces osteolytic lesions but not tumor burden in a murine model of myelomabone disease Blood 93 1697 706
25. OA O'Connor ML Heaney L Schwartz 2006 Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies J Clin Oncol 24 166 73 10.1200/JCO.2005.01.9679
26. PA Marks R Breslow 2007 Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug Nat Biotechnol 25 84 90 10.1038/nbt1272
27. A Nebbioso N Clarke E Voltz 2005 Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells Nat Med 11 77 84 10.1038/nm1161
28. S Inoue A Mai MJ Dyer GM Cohen 2006 Inhibition of histone deacetylase class I but not class II is critical for the sensitization of leukemic cells to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis Cancer Res 66 6785 92 10.1158/0008-5472.CAN-05-4563
29. A Kuendgen M Schmid R Schlenk 2006 The histone deacetylase (HDAC) inhibitor valproic acid as monotherapy or in combination with all-trans retinoic acid in patients with acute myeloid leukemia Cancer 106 112 9 10.1002/cncr.21552
30. M Abe S Kido M Hiasa 2006 BAFF and APRIL as osteoclast-derived survival factors for myeloma cells: a rationale for TACI-Fc treatment in patients with multiple myeloma Leukemia 20 1313 5 10.1038/sj.leu.2404228
31. Y Takada A Gillenwater H Ichikawa BB Aggarwal 2006 Suberoylanilide hydroxamic acid potentiates apoptosis, inhibits invasion, and abolishes osteoclastogenesis by suppressing nuclear factor-kappaB activation J Biol Chem 281 5612 22 10.1074/jbc.M507213200
32. T Nakamura T Kukita T Shobuike 2005 Inhibition of histone deacetylase suppresses osteoclastogenesis and bone destruction by inducing IFN-beta production J Immunol 175 5809 16
33. M Michaelis UR Michaelis I Fleming 2004 Valproic acid inhibits angiogenesis in vitro and in vivo Mol Pharmacol 65 520 7 10.1124/mol.65.3.520
34. RA Blaheta M Michaelis PH Driever J Cinatl Jr 2005 Evolving anticancer drug valproic acid: insights into the mechanism and clinical studies Med Res Rev 25 383 97 10.1002/med.20027
35. S Kumar SV Rajkumar 2006 Thalidomide and lenalidomide in the treatment of multiple myeloma Eur J Cancer 42 1612 22 10.1016/j.ejca.2006.04.004
36. RJ D'Amato S Lentzsch KC Anderson MS Rogers 2001 Mechanism of action of thalidomide and 3-aminothalidomide in multiple myeloma Semin Oncol 28 597 601 10.1053/sonc.2001.28601
37. Y Gazitt V Fey C Thomas R Alvarez 1998 Bcl-2 overexpression is associated with resistance to dexamethasone, but not melphalan, in multiple myeloma cells Int J Oncol 13 397 405
38. S Derenne B Monia NM Dean 2002 Antisense strategy shows that Mcl-1 rather than Bcl-2 or Bcl-x(L) is an essential survival protein of human myeloma cells Blood 100 194 9 10.1182/blood.V100.1.194
39. D Lavelle YH Chen M Hankewych J DeSimone 2001 Histone deacetylase inhibitors increase p21(WAF1) and induce apoptosis of human myeloma cell lines independent of decreased IL-6 receptor expression Am J Hematol 68 170 8 10.1002/ajh.1174
40. RJ Lin L Nagy S Inoue W Shao WH Miller Jr RM Evans 1998 Role of the histone deacetylase complex in acute promyelocytic leukaemia Nature 391 811 4 10.1038/35895
41. MR Trus L Yang F Suarez Saiz L Bordeleau I Jurisica MD Minden 2005 The histone deacetylase inhibitor valproic acid alters sensitivity towards all trans retinoic acid in acute myeloblastic leukemia cells Leukemia 19 1161 8 10.1038/sj.leu.2403773
42. JC Byrd G Marcucci MR Parthun 2005 A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia Blood 105 959 67 10.1182/blood-2004-05-1693
43. CS Mitsiades NS Mitsiades CJ McMullan 2004 Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications Proc Natl Acad Sci USA 101 540 5 10.1073/pnas.2536759100
44. L Catley E Weisberg YT Tai 2003 NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma Blood 102 2615 22 10.1182/blood-2003-01-0233
45. N Mitsiades CS Mitsiades PG Richardson 2003 Molecular sequelae of histone deacetylase inhibition in human malignant B cells Blood 101 4055 62 10.1182/blood-2002-11-3514
46. P Maiso X Carvajal-Vergara EM Ocio 2006 The histone deacetylase inhibitor LBH589 is a potent antimyeloma agent that overcomes drug resistance Cancer Res 66 5781 9 10.1158/0008-5472.CAN-05-4186
47. A Insinga S Monestiroli S Ronzoni 2005 Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway Nat Med 11 71 6 10.1038/nm1160
48. C Schwartz V Palissot N Aouali 2007 Valproic acid induces non-apoptotic cell death mechanisms in multiple myeloma cell lines Int J Oncol 30 573 82
49. TM Schroeder JJ Westendorf 2005 Histone deacetylase inhibitors promote osteoblast maturation J Bone Miner Res 20 2254 63 10.1359/JBMR.050813
50. HH Cho HT Park YJ Kim YC Bae KT Suh JS Jung 2005 Induction of osteogenic differentiation of human mesenchymal stem cells by histone deacetylase inhibitors J Cell Biochem 96 533 42 10.1002/jcb.20544
51. S Yaccoby MJ Wezeman M Zangari 2006 Inhibitory effects of osteoblasts and increased bone formation on myeloma in novel culture systems and a myelomatous mouse model Haematologica 91 192 9
52. S Yaccoby W Ling F Zhan R Walker B Barlogie JD Shaughnessy Jr 2007 Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo Blood 109 2106 11 10.1182/blood-2006-09-047712
53. A Palumbo S Bringhen T Caravita 2006 Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial Lancet 367 825 31 10.1016/S0140-6736(06)68338-4